BioCentury | Jan 12, 2015
Emerging Company Profile

Targeting transcription regulators

...which gained Fournier in 2010 through the acquisition of the pharmaceuticals business of Solvay S.A. Solvay...
...small molecule targeting an undisclosed nuclear receptor that originated within Fournier and was developed by Solvay...
...AbbVie Inc. (NYSE:ABBV), Chicago, Ill. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Inventiva S.A.S., Dijon, France Solvay S.A....
BioCentury | Mar 17, 2014
Clinical News

Flammacerium cerium nitrate/silver sulfadiazine regulatory update

...markets. Sinclair acquired Flammacerium, a cream containing 1% silver sulfadiazine and 2.2% cerium nitrate, from Solvay S.A....
BioCentury | Sep 9, 2013
Company News

CordenPharma International GmbH, Solvay deal

...Contract manufacturing provider CordenPharma will acquire Solvay's Peptisyntha S.A. business, which manufactures custom peptides for pharmaceutical...
...site offering peptide manufacturing. The companies could not be reached for details. The deal completes Solvay's...
...see BioCentury, Feb. 22, 2010 & Jan. 7, 2013). CordenPharma International GmbH , Plankstadt, Germany Solvay S.A....
BioCentury | Jun 24, 2013
Company News

AbbVie, Actavis, Solvay generics, genitourinary news

...of Appeals for the Eleventh Circuit that a pay-for-delay deal between the pharmaceuticals business of Solvay...
...had affirmed a district court's dismissal of the suit by the Federal Trade Commission against Solvay...
...antitrust law" within the scope of the patent. AbbVie, which acquired the pharmaceuticals business of Solvay...
BioCentury | Jun 18, 2013
Top Story

SCOTUS: pay-for-delay subject to antitrust litigation

...of Appeals for the Eleventh Circuit that a pay-for-delay deal between the pharmaceuticals business of Solvay S.A....
...had affirmed a district court's dismissal of the suit by the Federal Trade Commission against Solvay...
...would the patent." In a 5-3 AbbVie Inc. (NYSE:ABBV), which acquired the pharmaceuticals business of Solvay...
BioCentury | Jun 10, 2013
Company News

AbbVie sales and marketing update

...debuted in January. Abbott gained the product through Abbott's acquisition of the pharmaceuticals business of Solvay S.A....
BioCentury | Mar 27, 2013
Politics & Policy

SCOTUS hears oral arguments in pay-for-delay

...Solvay S.A. (Euronext:SOLB) and generic drug manufacturers, including Actavis Inc. (NYSE:ACT) (formerly Watson Pharmaceuticals Inc. ). Solvay...
...to the detriment of all consumers." AbbVie Inc. (NYSE:ABBV), which acquired the pharmaceuticals business of Solvay...
BioCentury | Mar 25, 2013
Company News

Sinclair IS Pharma, Hikma Pharmaceuticals sales and marketing update

...nitrate is marketed to treat and prevent infections in burn wounds. Sinclair has rights from Solvay S.A....
BioCentury | Dec 17, 2012
Company News

Abbott, Par Pharmaceutical, Perrigo, Watson endocrine/metabolic news

...Federal Trade Commission v. Watson Pharmaceuticals Inc., the FTC alleged that the pharmaceuticals business of Solvay S.A....
...of a 2006 suit in the U.S. District Court for the Northern District of Georgia, Solvay...
...of the patent. Abbott gained the product through its acquisition of the pharmaceuticals business of Solvay...
BioCentury | Dec 10, 2012
Company News

Medigene, Nordic Group sales and marketing update

...Veregen is already approved in the U.S., Germany, Austria, Spain, Slovakia, Poland and Hungary. The Solvay...
Items per page:
1 - 10 of 435
BioCentury | Jan 12, 2015
Emerging Company Profile

Targeting transcription regulators

...which gained Fournier in 2010 through the acquisition of the pharmaceuticals business of Solvay S.A. Solvay...
...small molecule targeting an undisclosed nuclear receptor that originated within Fournier and was developed by Solvay...
...AbbVie Inc. (NYSE:ABBV), Chicago, Ill. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Inventiva S.A.S., Dijon, France Solvay S.A....
BioCentury | Mar 17, 2014
Clinical News

Flammacerium cerium nitrate/silver sulfadiazine regulatory update

...markets. Sinclair acquired Flammacerium, a cream containing 1% silver sulfadiazine and 2.2% cerium nitrate, from Solvay S.A....
BioCentury | Sep 9, 2013
Company News

CordenPharma International GmbH, Solvay deal

...Contract manufacturing provider CordenPharma will acquire Solvay's Peptisyntha S.A. business, which manufactures custom peptides for pharmaceutical...
...site offering peptide manufacturing. The companies could not be reached for details. The deal completes Solvay's...
...see BioCentury, Feb. 22, 2010 & Jan. 7, 2013). CordenPharma International GmbH , Plankstadt, Germany Solvay S.A....
BioCentury | Jun 24, 2013
Company News

AbbVie, Actavis, Solvay generics, genitourinary news

...of Appeals for the Eleventh Circuit that a pay-for-delay deal between the pharmaceuticals business of Solvay...
...had affirmed a district court's dismissal of the suit by the Federal Trade Commission against Solvay...
...antitrust law" within the scope of the patent. AbbVie, which acquired the pharmaceuticals business of Solvay...
BioCentury | Jun 18, 2013
Top Story

SCOTUS: pay-for-delay subject to antitrust litigation

...of Appeals for the Eleventh Circuit that a pay-for-delay deal between the pharmaceuticals business of Solvay S.A....
...had affirmed a district court's dismissal of the suit by the Federal Trade Commission against Solvay...
...would the patent." In a 5-3 AbbVie Inc. (NYSE:ABBV), which acquired the pharmaceuticals business of Solvay...
BioCentury | Jun 10, 2013
Company News

AbbVie sales and marketing update

...debuted in January. Abbott gained the product through Abbott's acquisition of the pharmaceuticals business of Solvay S.A....
BioCentury | Mar 27, 2013
Politics & Policy

SCOTUS hears oral arguments in pay-for-delay

...Solvay S.A. (Euronext:SOLB) and generic drug manufacturers, including Actavis Inc. (NYSE:ACT) (formerly Watson Pharmaceuticals Inc. ). Solvay...
...to the detriment of all consumers." AbbVie Inc. (NYSE:ABBV), which acquired the pharmaceuticals business of Solvay...
BioCentury | Mar 25, 2013
Company News

Sinclair IS Pharma, Hikma Pharmaceuticals sales and marketing update

...nitrate is marketed to treat and prevent infections in burn wounds. Sinclair has rights from Solvay S.A....
BioCentury | Dec 17, 2012
Company News

Abbott, Par Pharmaceutical, Perrigo, Watson endocrine/metabolic news

...Federal Trade Commission v. Watson Pharmaceuticals Inc., the FTC alleged that the pharmaceuticals business of Solvay S.A....
...of a 2006 suit in the U.S. District Court for the Northern District of Georgia, Solvay...
...of the patent. Abbott gained the product through its acquisition of the pharmaceuticals business of Solvay...
BioCentury | Dec 10, 2012
Company News

Medigene, Nordic Group sales and marketing update

...Veregen is already approved in the U.S., Germany, Austria, Spain, Slovakia, Poland and Hungary. The Solvay...
Items per page:
1 - 10 of 435